• Hania Szajewska, Maciej Kołodziej, and Bartłomiej M Zalewski.
• Department of Paediatrics, The Medical University of Warsaw, Warsaw, Poland.
• Aliment. Pharmacol. Ther. 2020 Apr 1; 51 (7): 678-688.

BackgroundThere is still controversy with regard to the efficacy of individual probiotic strains for the management of acute gastroenteritis.AimTo update evidence on use of Saccharomyces boulardii for treating acute gastroenteritis in children.MethodsThe Cochrane Library, MEDLINE and EMBASE databases were searched from inception to December 2019 for randomised controlled trials (RCTs) that compared use of S boulardii with no S boulardii (defined as placebo or no treatment). The grey literature was searched through Google search. Authors of the original papers and S boulardii manufacturers were contacted for additional data.ResultsTwenty-nine RCTs (among them, 20 newly identified trials) were included. Only 38% of trials adequately generated their randomisation sequence, only 17% adequately concealed allocation and only one trial adequately blinded participants, study personnel and outcome assessors. However, 83% provided complete outcome data. None of the trials evaluated the effect of S boulardii on stool volume. Compared with placebo or no treatment, S boulardii use reduced the duration of diarrhoea (23 RCTs, n = 3450, mean difference -1.06 day, 95% CI -1.32 to -0.79; high heterogeneity [I2  = 90%]) (very low quality of evidence). S boulardii use was also associated with a reduced duration of hospitalisation (8 RCTs, n = 999, mean difference -0.85 day, 95% CI -1.35 to -0.34; I2  = 91%) (very low quality of evidence). S boulardii reduced the risk of diarrhoea on day 2 to day 7 (low quality of evidence).ConclusionsIn children with acute gastroenteritis, low- to very low-quality evidence suggests that S boulardii confers a benefit for several diarrhoeal outcomes.© 2020 John Wiley & Sons Ltd.

25 keywords...

hide…